Leidos Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Leidos Holdings wird ein jährliches Gewinn- und Umsatzwachstum von 4.7% bzw. 5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 8.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 24.1% betragen.

Wichtige Informationen

4.7%

Wachstumsrate der Gewinne

8.10%

EPS-Wachstumsrate

Professional Services Gewinnwachstum	14.5%
Wachstumsrate der Einnahmen	5.0%
Zukünftige Eigenkapitalrendite	24.08%
Analystenabdeckung	Good
Zuletzt aktualisiert	10 Sep 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Narrative-Update • Sep 03

Leidos Holdings: The Unseen Cash Flow Machine Fueling Aggressive Buybacks In Defense

Summary Leidos is deeply undervalued, with a STRONG BUY rating supported by robust free cash flow and an asset-light business model. LDOS benefits from inelastic, recession-proof government defense spending, long-term cost-plus contracts, and high revenue visibility via a substantial backlog. Segment restructuring reveals a blend of stable, inflation-indexed government revenue and high-margin health & civil operations, enhancing cash flow and resilience. DCF, relative, and dividend models all indicate 96–315% upside potential, with significant margin of safety even in pessimistic scenarios. Read the full article on Seeking Alpha

Narrative-Update • Jul 09

LDOS: AI Contracts And Defense Wins Will Offset Healthcare Headwinds

The analyst price target for Leidos Holdings has been reduced by about $13, reflecting updated assumptions for slightly lower revenue growth, a marginally higher discount rate, modestly softer profit margins, and a lower future P/E multiple as analysts factor in pressures in the healthcare portfolio and adopt more cautious expectations for organic growth. Analyst Commentary Recent Street research on Leidos Holdings shows a split view, with some bullish analysts still positive on the company’s long term growth and others turning more cautious as they rethink expectations around organic growth, healthcare exposure, and valuation multiples.

Neues Narrative • Jul 02

AI And Cyber Pipelines Will Shape A Balanced Long Term Outlook

Catalysts About Leidos Holdings Leidos Holdings is a technology and engineering company that provides solutions in defense, intelligence, health, and infrastructure, primarily for U.S. government customers. What are the underlying business or industry changes driving this perspective?

Narrative-Update • Jun 25

LDOS: Healthcare Headwinds Will Set Up Future Re Rating Opportunity

The updated analyst price target framework for Leidos Holdings edges lower, with fair value moving from $183.27 to $178.27 as analysts factor in recent downgrades, reduced targets tied to healthcare contract pressure, and more cautious assumptions for organic growth, margins, and future P/E. Analyst Commentary Recent Street research on Leidos Holdings has tilted more cautious, with several bearish analysts revisiting ratings and price targets as they reassess healthcare exposure, organic growth expectations, and earnings power.

Neues Narrative • Jun 17

Leidos Stock Will Ride NorthStar 2030 And AI Missions For Long-Term Upside

Catalysts About Leidos Holdings Leidos Holdings is a technology-focused defense, intelligence, health, and infrastructure company that delivers mission-critical systems, services, and products to government and commercial customers. What are the underlying business or industry changes driving this perspective?

Analyseartikel • Jun 17

Leidos Holdings (LDOS) Stock Could Be 38% Undervalued After Downgrade And DHA Contract Pressure

Leidos Holdings (LDOS) is back in focus after a Jefferies downgrade and fresh concerns about profit margins and U.S. defense budgets, along with additional pressure from changes to a key Defense Health Agency contract. See our latest analysis for Leidos Holdings. Leidos Holdings has come under pressure, with the share price down 31.9% over the past 90 days and the 1 year total shareholder return declining 23.2%, although the 3 year total shareholder return of 38.0% still reflects earlier...

Narrative-Update • Jun 10

LDOS: Hypersonic Weapons Production Contract Will Drive Future Re Rating Potential

Analysts have trimmed their fair value estimate for Leidos Holdings by about $3 to $183.27, reflecting lower organic growth and profit margin assumptions after several firms cut price targets, including a Jefferies downgrade to Hold and reduced long term EPS expectations. This was partly offset by fresh positive coverage such as an Outperform initiation at BNP Paribas with a $165 target.

Narrative-Update • May 27

LDOS: Federal IT Wins And Hypersonic Programs Will Support Re Rating

Leidos Holdings' analyst price target has been revised lower by roughly $13 to about $186, as analysts update their models for a higher discount rate, a lower future P/E, and refreshed views from recent target cuts and a neutral initiation alongside one target increase. Analyst Commentary Recent Street research on Leidos Holdings has centered on recalibrated price targets, with several reductions and one increase, along with a fresh neutral initiation.

Narrative-Update • May 02

LDOS: Defense Tech Contracts And AI Alliance Will Offset 2026 VBA Drag

The updated analyst price target for Leidos Holdings has been trimmed by about $5 to roughly $199 per share. Analysts factored in recent target cuts around mixed Q4 results, modestly lower revenue growth assumptions, a slightly higher discount rate, and a somewhat lower future P/E multiple, even as profit margin expectations edge up.

Narrative-Update • Apr 17

LDOS: Defense Tech And AI Partnership Will Offset 2026 VBA Headwinds

Leidos Holdings' updated analyst price target has moved lower by about $5 per share to reflect a slightly higher discount rate, a reduced future P/E assumption, and tempered margin expectations, as analysts factor in mixed Q4 results, recent target cuts from several firms, and ongoing headwinds in Veterans Benefits Administration work, even as growth initiatives continue. Analyst Commentary Recent research updates on Leidos point to a more cautious valuation framework, even as some analysts still see upside tied to growth investments and capital allocation changes.

Narrative-Update • Apr 03

LDOS: Defense Tech And AI Contracts Will Offset 2026 VBA Slowdown

Analysts have trimmed the average price target for Leidos Holdings to $209 from about $212, reflecting slightly higher discount rate assumptions, modestly adjusted growth and margin expectations, and mixed reactions to recent Q4 results and contract headwinds. Analyst Commentary Recent research paints a mixed picture around Leidos Holdings, with both optimistic and cautious views emerging after the latest Q4 report, updated guidance, and evolving contract exposure.

Narrative-Update • Mar 19

LDOS: Defense Tech And AI Expansion Will Offset 2026 VBA Contract Slowdown

Analysts have trimmed the blended price target on Leidos Holdings by about $1.50 to roughly $212.50, reflecting slightly softer long term growth and margin assumptions after mixed Q4 results and evolving views on the VBA headwind and defense tech opportunities. Analyst Commentary Street research on Leidos Holdings has shifted toward a more balanced view, with price targets generally nudged lower and ratings clustered around Buy, Outperform, Hold, and Neutral.

Narrative-Update • Mar 05

LDOS: Defense Tech And AI Shift Will Offset 2026 VBA Headwinds

Analysts have reduced their blended price target for Leidos Holdings by about $4 to roughly $214, reflecting recent Q4 updates, mixed views on growth in 2026, and ongoing debate around the impact of slower Veterans Benefits Administration work versus opportunities in defense tech and other growth segments. Analyst Commentary Street research on Leidos presents a split view, with several firms trimming price targets after Q4 while still highlighting long term growth opportunities in defense technology and other higher growth areas.

Narrative-Update • Feb 18

LDOS: Defense Tech And AI Shift Will Support Premium Multiple

The updated fair value estimate for Leidos Holdings edges down to about $218 per share from roughly $219, as analysts adjust price targets lower, citing mixed Q4 results, a slowdown in Veterans Benefits Administration activity, and tempered views on future valuation and guidance, even as the company increases its focus on higher growth markets. Analyst Commentary Recent Street research on Leidos points to a split view, with some analysts focusing on long term growth opportunities and others stressing execution risks and valuation constraints following the latest Q4 report and guidance.

Narrative-Update • Feb 04

LDOS: Entrust Acquisition And AI Partnerships Will Support Premium Multiple

Analysts nudged their blended price target on Leidos Holdings slightly higher to about US$219.31, reflecting a modestly higher assumed future P/E multiple while balancing recent target moves tied to enthusiasm around the Entrust acquisition and caution over potential 2026 contract headwinds. Analyst Commentary Recent research on Leidos highlights a split view, with some analysts leaning into the potential of the Entrust acquisition and others more focused on contract concentration and 2026 risk.

Narrative-Update • Jan 21

LDOS: Health And Civil Strength And VA Contract Risk Will Shape Premium Multiple

Narrative Update: Leidos Holdings Analysts have trimmed their blended price target on Leidos Holdings by about $1 per share to $219, reflecting slightly more conservative assumptions on revenue growth, margins, and future P/E, after balancing recent target increases from firms citing strong execution and portfolio positioning with concerns around a key high margin contract and the timing of proving its sustainability. Analyst Commentary Recent research on Leidos highlights a mix of optimism around the core business and caution around a key contract that could affect medium term growth and valuation multiples.

Narrative-Update • Jan 07

LDOS: Health And Civil Strength And Pipeline Visibility Will Support Premium Multiple

Analysts have nudged their fair value estimate for Leidos Holdings higher to about $219.85 from roughly $218.08, citing stronger recent earnings, solid Health & Civil margins, a 1.3x book to bill, a US$69b near term pipeline, and a view that the company merits a premium P/E multiple within government services. Analyst Commentary Bullish Takeaways Bullish analysts see the recent earnings beat as support for a higher fair value, pointing to execution in Health & Civil margins as a key driver of profitability.

Narrative-Update • Dec 16

LDOS: Strong Health And Civil Margins Will Support Future Premium Multiple

Analysts have raised their price target on Leidos Holdings to approximately $218.08 per share from about $218.08. This reflects slightly stronger expectations for revenue growth and sustained margins, supported by robust book to bill trends, a sizable near term pipeline, and upside earnings performance with higher profitability guidance into 2025.

Narrative-Update • Dec 02

LDOS: Strong Health And Civil Margins Will Support Continued Margin Upside

Leidos Holdings saw its average analyst price target rise from $210 to $230 as analysts highlighted robust Health & Civil margins, a strong contract pipeline, and increased profitability guidance following recent earnings results. Analyst Commentary Recent analyst reports have highlighted several factors influencing sentiment around Leidos Holdings following the latest earnings results and guidance updates.

Narrative-Update • Nov 18

LDOS: Near-Term Contract Pipeline Will Drive Continued Margin Upside

Leidos Holdings' analyst price target has increased from $201.83 to $218.08 per share, as analysts cite strong margins in Health and Civil segments, a robust $69 billion pipeline, and raised profitability guidance as driving factors for the upward revision. Analyst Commentary Recent analyst reports have highlighted several factors that shape both the bullish and cautious outlooks for Leidos Holdings following its stronger-than-expected earnings performance and revised guidance.

Analyseartikel • Nov 06

Leidos Holdings (NYSE:LDOS) Is Increasing Its Dividend To $0.43

Leidos Holdings, Inc. ( NYSE:LDOS ) will increase its dividend from last year's comparable payment on the 31st of...

Narrative-Update • Nov 02

LDOS: Federal Health And Security Spending Will Drive Steady Performance Ahead

Leidos Holdings saw its analyst price target rise from approximately $198.50 to $201.83. Analysts cited the company’s ongoing momentum in health services, robust margins, and its positioning to benefit from expanding federal funding priorities.

Narrative-Update • Oct 18

Government Funding And Digital Transformation Will Create Future Value

The average analyst price target for Leidos Holdings was raised by approximately $4 to $198.50. Analysts highlighted improving healthcare margins, stronger execution in health and defense services, and the company's positioning to benefit from recent government funding priorities.

Narrative-Update • Oct 04

Government Funding And Digital Transformation Will Create Future Value

The analyst price target for Leidos Holdings has been increased by approximately $2 to $194.71, as analysts cite ongoing strength in healthcare margins, opportunities in defense solutions, and improved business execution as key factors supporting the higher valuation. Analyst Commentary Recent Street research updates reflect a generally positive outlook on Leidos Holdings, with multiple analysts raising their price targets and upgrading the stock in response to improved business execution and strong performance in key sectors.

Narrative-Update • Sep 19

Government Funding And Digital Transformation Will Create Future Value

Upward analyst revisions for Leidos Holdings reflect confidence in its strategic investments in health and border security, strong healthcare margins, and effective leadership, resulting in a modest price target increase from $190.15 to $192.66. Analyst Commentary Bullish analysts highlight Leidos' strategic investments in veteran health, border security, and autonomous maritime, positioning the company to benefit from new government funding priorities.

Narrative-Update • Sep 04

Government Funding And Digital Transformation Will Create Future Value

Analysts maintain a positive outlook on Leidos Holdings due to strong execution in Health Services, favorable positioning for government funding priorities, increased management confidence, and a strategic pivot toward higher-margin growth sectors, resulting in an unchanged $186.69 price target. Analyst Commentary Continued strength and solid execution within Leidos' Health Services business, contributing to improved outlook and confidence.

Gewinn- und Umsatzwachstumsprognosen

NYSE:LDOS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	20,088	1,549	1,741	1,952	12
12/31/2027	19,184	1,443	1,630	1,849	16
12/31/2026	18,322	1,384	1,588	1,836	16
7/3/2026	17,634	1,376	2,163	2,300	N/A
4/3/2026	17,329	1,413	1,859	1,993	N/A
1/2/2026	17,174	1,448	1,625	1,750	N/A
10/3/2025	17,332	1,405	1,338	1,506	N/A
7/4/2025	17,053	1,402	1,325	1,485	N/A
4/4/2025	16,932	1,333	1,226	1,380	N/A
1/3/2025	16,662	1,254	1,286	1,435	N/A
9/27/2024	16,277	1,199	1,304	1,445	N/A
6/28/2024	16,008	436	1,425	1,593	N/A
3/29/2024	15,714	321	1,191	1,376	N/A
12/29/2023	15,438	199	980	1,187	N/A
9/29/2023	15,155	147	804	986	N/A
6/30/2023	14,842	708	761	920	N/A
3/31/2023	14,601	672	661	801	N/A
12/30/2022	14,396	685	863	992	N/A
9/30/2022	14,190	682	968	1,077	N/A
7/1/2022	14,065	725	807	913	N/A
4/1/2022	13,916	723	779	885	N/A
12/31/2021	13,737	753	929	1,033	N/A
10/1/2021	13,498	776	635	769	N/A
7/2/2021	13,257	734	656	796	N/A
4/2/2021	12,723	718	1,036	1,201	N/A
1/1/2021	12,297	628	1,151	1,334	N/A
10/2/2020	11,999	612	1,381	1,555	N/A
7/3/2020	11,592	610	1,147	1,312	N/A
4/3/2020	11,406	593	N/A	1,076	N/A
1/3/2020	11,094	667	N/A	992	N/A
9/27/2019	10,787	674	N/A	927	N/A
6/28/2019	10,527	660	N/A	949	N/A
3/29/2019	10,328	668	N/A	1,034	N/A
12/28/2018	10,194	581	N/A	768	N/A
9/28/2018	10,063	507	N/A	828	N/A
6/29/2018	9,991	442	N/A	724	N/A
3/30/2018	10,033	396	N/A	619	N/A
12/29/2017	10,170	366	N/A	526	N/A
9/29/2017	10,229	311	N/A	483	N/A
6/30/2017	9,594	320	N/A	486	N/A
3/31/2017	8,311	263	N/A	392	N/A
12/30/2016	7,043	244	N/A	449	N/A
9/30/2016	5,803	341	N/A	365	N/A
7/1/2016	5,237	299	N/A	364	N/A
4/1/2016	5,206	295	N/A	443	N/A
1/1/2016	5,140	265	N/A	409	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: LDOSDas prognostizierte Gewinnwachstum (4.7% pro Jahr) liegt über der Sparquote (3.7%).

Ertrag vs. Markt: LDOSDie Erträge des Unternehmens (4.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (17.2% pro Jahr).

Hohe Wachstumserträge: LDOSDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: LDOSDie Einnahmen des Unternehmens (5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (13.4% pro Jahr).

Hohe Wachstumseinnahmen: LDOSDie Einnahmen des Unternehmens (5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: LDOSDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (24.1%)

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/09/14 22:13
Aktienkurs zum Tagesende	2026/09/14 00:00
Gewinne	2026/07/03
Jährliche Einnahmen	2026/01/02

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Leidos Holdings, Inc. wird von 24 Analysten beobachtet. 16 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
John Eade	Argus Research Company
Peter Arment	Baird
David Strauss	Barclays

Leidos Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Leidos Holdings, Inc. Raises Earnings Guidance for the Fiscal Year 2026

Price target decreased by 8.5% to US$158

Price target decreased by 7.3% to US$165

Price target decreased by 8.0% to US$183

Leidos Holdings, Inc. Raises Earnings Guidance for the Fiscal Year 2026

Leidos Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2026

Recent updates

Leidos Autonomous Vessels Achieve Milestone Deployments With US Navy at RIMPAC and at Sea

Upcoming dividend of US$0.43 per share

Independent Director recently sold US$141k worth of stock

LDOS: Cyber And AI Contract Wins Will Balance Health Segment Pressure

Leidos Secures Five-Year Deal to Expand US Military Cyber Defense Capabilities

LDOS: Defense And Edge AI Strength Will Offset Health Uncertainty

Independent Director recently sold US$1.4m worth of stock

Independent Director notifies of intention to sell stock

Investor sentiment improves as stock rises 17%

LDOS: AI And Defense Contracts Will Drive Future Repricing Debate

Second quarter dividend of US$0.43 announced

Leidos Wins Major Missile Defense Satellite Payload Contract With Sierra Space

Leidos Holdings, Inc. Raises Earnings Guidance for the Fiscal Year 2026

Second quarter 2026 earnings: EPS and revenues exceed analyst expectations

Leidos Holdings, Inc. Declares Quarterly Cash Dividend, Payable on September 30, 2026

Leidos Wins $717 Million US Air Force Task Order for ISR Operations

Leidos Introduces Parcata AI Platform to Find and Fix Cybersecurity Vulnerabilities

Leidos Unveils Live Cyber Threat Detection Success at Valiant Shield 2026 Exercise

LDOS: AI Logistics Partnerships Will Drive Future Repricing Debate

Leidos and DHL Alliance Targets UK Defence Logistics with Advanced Technology Integration

Leidos Holdings: The Unseen Cash Flow Machine Fueling Aggressive Buybacks In Defense

Price target decreased by 8.5% to US$158

Leidos And Rune Technologies Partner To Accelerate AI-Enabled Predictive Logistics And Sustainment Mission Command Software

LDOS: AI Contracts And Defense Wins Will Offset Healthcare Headwinds

Price target decreased by 7.3% to US$165

Leidos Holdings, Inc. to Report Q2, 2026 Results on Aug 04, 2026

AI And Cyber Pipelines Will Shape A Balanced Long Term Outlook

LDOS: Healthcare Headwinds Will Set Up Future Re Rating Opportunity

Leidos Advances Military Energy Tech With New DARPA ExCURSion Collaboration

Leidos Stock Will Ride NorthStar 2030 And AI Missions For Long-Term Upside

Leidos Holdings (LDOS) Stock Could Be 38% Undervalued After Downgrade And DHA Contract Pressure

Leidos Shares Reach Two-Year Low as Key Defense Contract Set to End

LDOS: Hypersonic Weapons Production Contract Will Drive Future Re Rating Potential

Upcoming dividend of US$0.43 per share

Leidos Debuts Joint SATCOM Tool Offering Real-Time Visibility for Defense Communications

Price target decreased by 8.0% to US$183

LDOS: Federal IT Wins And Hypersonic Programs Will Support Re Rating

Independent Director exercised options and sold US$197k worth of stock

Leidos Holdings, Inc. Raises Earnings Guidance for the Fiscal Year 2026

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter dividend of US$0.43 announced

Leidos Holdings, Inc. Declares A Quarterly Cash Dividend, Payable on June 30, 2026

LDOS: Defense Tech Contracts And AI Alliance Will Offset 2026 VBA Drag

LDOS: Defense Tech And AI Partnership Will Offset 2026 VBA Headwinds

Leidos Holdings, Inc. to Report Q1, 2026 Results on May 05, 2026

LDOS: Defense Tech And AI Contracts Will Offset 2026 VBA Slowdown

Leidos Holdings, Inc., Annual General Meeting, May 01, 2026

LDOS: Defense Tech And AI Expansion Will Offset 2026 VBA Contract Slowdown

Independent Director exercised options to buy US$1.1m worth of stock.

Upcoming dividend of US$0.43 per share

LDOS: Defense Tech And AI Shift Will Offset 2026 VBA Headwinds

Fourth quarter dividend of US$0.43 announced

LDOS: Defense Tech And AI Shift Will Support Premium Multiple

Third quarter 2025 earnings released: EPS: US$2.87 (vs US$2.70 in 3Q 2024)

Investor sentiment deteriorates as stock falls 17%

Leidos Holdings, Inc. Provides Earnings Guidance for the Fiscal Year 2026

Leidos Holdings, Inc. Declares Quarterly Cash Dividend, Payable on March 31, 2026

Leidos Holdings, Inc. to Launch Next Phase of Dodnet Transformation Through Accelerated Migration of Defense Agencies

LDOS: Entrust Acquisition And AI Partnerships Will Support Premium Multiple

LDOS: Health And Civil Strength And VA Contract Risk Will Shape Premium Multiple

Leidos Holdings, Inc. to Report Q4, 2025 Results on Feb 17, 2026

LDOS: Health And Civil Strength And Pipeline Visibility Will Support Premium Multiple

LDOS: Strong Health And Civil Margins Will Support Future Premium Multiple

Leidos Holdings, Inc. Announces Executive Changes, Effective January 5, 2026

Upcoming dividend of US$0.43 per share

LDOS: Strong Health And Civil Margins Will Support Continued Margin Upside

LDOS: Near-Term Contract Pipeline Will Drive Continued Margin Upside

Price target increased by 8.1% to US$218

Price target increased by 8.6% to US$216